Skip to main content

5 Result(s)

within Isao Fujioka Remove this filter

and

  1. No Access

    Article

    Bosutinib-induced late-onset severe liver injury preceded by eosinophilia

    Tyrosine kinase inhibitors (TKIs) have dramatically changed the way chronic myeloid leukemia (CML) is treated. Although TKI therapy improves the overall survival of patients with CML, the management of various...

    Naoki Watanabe, Tomoiku Takaku, Isao Fujioka, Shun Tsuchiya… in Annals of Hematology (2022)

  2. No Access

    Article

    Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database

    This study investigated the incidence rate and features of vascular adverse events (VAEs) in Japanese patients with chronic myeloid leukemia (CML) who were treated with tyrosine kinase inhibitors (TKIs). The a...

    Isao Fujioka, Tomoiku Takaku, Noriyoshi Iriyama, Michihide Tokuhira… in Annals of Hematology (2018)

  3. No Access

    Article

    Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis

    Treatment with a tyrosine kinase inhibitor (TKI) is the standard of care for patients with chronic myeloid leukemia (CML). The new-generation TKIs, nilotinib and dasatinib, are found to have deeper and faster ...

    Noriyoshi Iriyama, Kei-Ji Sugimoto, Eriko Sato, Tomoiku Takaku… in Medical Oncology (2018)

  4. No Access

    Article

    Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors

    We performed a retrospective study to evaluate the incidence of second malignancies (SMs) in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We analyzed data from 339 pa...

    Tomonori Nakazato, Noriyoshi Iriyama, Michihide Tokuhira, Maho Ishikawa… in Medical Oncology (2018)

  5. No Access

    Article

    Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase

    ABL1-tyrosine kinase inhibitors (TKIs) have led to dramatic changes in treatment strategies for chronic myeloid leukemia in the chronic phase (CML-CP). However, clinical studies have highlighted increasing num...

    Michihide Tokuhira, Yuta Kimura, Keiji Sugimoto, Tomonori Nakazato… in Medical Oncology (2018)